Overexpression of Mutant P53 and C-erbB-2 Proteins and Breast Tumour Take in Mice

Overview

Journal Br J Cancer

Specialty Oncology

Date 1995 Nov 1

PMID 7577462

Citations 3

Authors

R R Mehta

J M GRAVES

M A Warso

T K Das Gupta

Affiliations

Soon will be listed here.

Abstract

We established a panel of 17 xenografts from primary human breast carcinomas. We examined which characteristics of the original tumours and the xenografts facilitate growth in animals. Tumours expressing medium or strong immunoreactivity for p53 protein had significantly (P < 0.05) higher incidence (92%) of in vivo tumour take than those showing weak or negative immunoreactivity (9.1%). No such association was observed between either c-erbB-2 or epidermal growth factor receptor (EGFR) expression in the original tumours and their in vivo tumour take. Following subcutaneous (s.c.) transplantation of original breast tumours or established xenografts, 7/17 tumours showed metastatic disease spread to distant sites (mainly lungs). This study suggests that selective growth of highly aggressive tumours occurs during in vivo propagation of malignant tumours, and these tumours will be of particular interest in evaluating various chemotherapeutic agents for breast cancer management.

Citing Articles

Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells.

Huang G, Hobbs S, Walton M, Epstein R Br J Cancer. 2002; 86(7):1104-9.

PMID: 11953857 PMC: 2364174. DOI: 10.1038/sj.bjc.6600219.

Development of a new metastatic human breast carcinoma xenograft line.

Mehta R, GRAVES J, Shilkaitis A, Das Gupta T Br J Cancer. 1998; 77(4):595-604.

PMID: 9484817 PMC: 2149914. DOI: 10.1038/bjc.1998.96.

Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.

Wani G, Noyes I, Milo G, DAmbrosio S Mol Med. 1997; 3(4):273-83.

PMID: 9131589 PMC: 2230072.

References

Gimbrone Jr M, Leapman S, COTRAN R, Folkman J . Tumor dormancy in vivo by prevention of neovascularization. J Exp Med. 1972; 136(2):261-76. PMC: 2139203. DOI: 10.1084/jem.136.2.261. View

Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O . Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol. 1994; 12(3):454-66. DOI: 10.1200/JCO.1994.12.3.454. View

Reid L . Growth of human breast carcinomas in nude mice and subsequent establishment in tissue culture. Cancer Res. 1980; 40(1):95-100. View

Barsky S, Rao C, Williams J, Liotta L . Laminin molecular domains which alter metastasis in a murine model. J Clin Invest. 1984; 74(3):843-8. PMC: 425239. DOI: 10.1172/JCI111501. View

Terranova V, Williams J, Liotta L, Martin G . Modulation of the metastatic activity of melanoma cells by laminin and fibronectin. Science. 1984; 226(4677):982-5. DOI: 10.1126/science.6505678. View

GIOVANELLA B, Fogh J . The nude mouse in cancer research. Adv Cancer Res. 1985; 44:69-120. DOI: 10.1016/s0065-230x(08)60026-3. View

Sabiston P, Adams M, Ho Y . Automation of 1,9-dimethylmethylene blue dye-binding assay for sulfated glycosaminoglycans with application to cartilage microcultures. Anal Biochem. 1985; 149(2):543-8. DOI: 10.1016/0003-2697(85)90611-6. View

Liotta L, Rao C, Wewer U . Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem. 1986; 55:1037-57. DOI: 10.1146/annurev.bi.55.070186.005133. View

Furcht L . Critical factors controlling angiogenesis: cell products, cell matrix, and growth factors. Lab Invest. 1986; 55(5):505-9. View

10.

Thor A, Schwartz L, Koerner F, Edgerton S, Skates S, Yin S . Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res. 1989; 49(24 Pt 1):7147-52. View

11.

Fridman R, Giaccone G, KANEMOTO T, Martin G, Gazdar A, Mulshine J . Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 1990; 87(17):6698-702. PMC: 54604. DOI: 10.1073/pnas.87.17.6698. View

12.

GIOVANELLA B, Vardeman D, Williams L, Taylor D, De Ipolyi P, Greeff P . Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. Int J Cancer. 1991; 47(1):66-71. DOI: 10.1002/ijc.2910470113. View

13.

Sakamoto N, Iwahana M, Tanaka N, Osada Y . Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2. Cancer Res. 1991; 51(3):903-6. View

14.

WOLMAN S, Feiner H, Schinella R, Gimotty P, Ownby H, Maloney T . A retrospective analysis of breast cancer based on outcome differences. Hum Pathol. 1991; 22(5):475-80. DOI: 10.1016/0046-8177(91)90134-b. View

15.

Fridman R, Kibbey M, Royce L, Zain M, Sweeney M, Jicha D . Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel. J Natl Cancer Inst. 1991; 83(11):769-74. DOI: 10.1093/jnci/83.11.769. View

16.

Pretlow T, Delmoro C, Dilley G, Spadafora C, Pretlow T . Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res. 1991; 51(14):3814-7. View

17.

Kallioniemi O, Holli K, Visakorpi T, Koivula T, Helin H, Isola J . Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991; 49(5):650-5. DOI: 10.1002/ijc.2910490504. View

18.

Taylor W, Egan S, Mowat M, Greenberg A, Wright J . Evidence for synergistic interactions between ras, myc and a mutant form of p53 in cellular transformation and tumor dissemination. Oncogene. 1992; 7(7):1383-90. View

19.

Mehta R, Bratescu L, GRAVES J, Hart G, Shilkaitis A, Green A . Human breast carcinoma cell lines: ultrastructural, genotypic, and immunocytochemical characterization. Anticancer Res. 1992; 12(3):683-92. View

20.

Passaniti A, Taylor R, Pili R, Guo Y, Long P, Haney J . A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest. 1992; 67(4):519-28. View